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Abstract
Most patients with ovarian cancer present at an advanced stage and are never cured. To 
improve outcomes a variety of novel systemic strategies are being developed. Traditional 
cytotoxic chemotherapy is being optimised, anti-angiogenic strategies are already in the 
clinic and several PARP inhibitors have gained regulatory approval. In addition, immu-
notherapy is showing promise and novel targeted strategies including against folate 
receptor alpha are also generating excitement. As our therapeutic choice increases, a chal-
lenge will be how to best utilize the options available. Here we discuss recently estab-
lished and other emerging therapies with a focus on key concepts rather than detailed 
synopses of trial designs and outcomes.
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1. Introduction
Over a quarter of a million women are diagnosed with epithelial ovarian cancer (EOC1) each 
year and it is responsible for around 140,000 deaths worldwide. There is no effective screening 
program so the majority present with advanced disease. Despite improved surgical technique 
most patients are never cured. Novel systemic treatments are needed both to prolong overall 
survival with the disease but also increase the fraction of patients in whom cure is achieved. A 
variety of distinct but complementary approaches are discussed here.
1In this chapter, EOC refers also to primary peritoneal and fallopian tube carcinoma. Definitions of platinum-sensitive, 
resistant and refractory are as per the relevant citation.
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the t rms of the Crea ive
Comm ns Attribution Lic nse (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
2. Chemotherapy in ovarian cancer
Despite the emergence of alternate antineoplastic strategies, chemotherapy remains the back-
bone of EOC treatment. Although EOC is chemosensitive, with most patients responding 
initially, the majority will eventually relapse and subsequent responses are poorer. Efforts 
are being made to try and enhance the efficacy of ‘traditional’ cytotoxic chemotherapy. These 
include manipulation of dosing schedules, efforts to understand resistance and discovery of 
novel agents. These strategies are discussed in this subsection.
2.1. Dose-dense chemotherapy
Dose densification refers to the administration of an agent more frequently than in the ‘stan-
dard’ regimen. It can imply dose intensification (i.e. increasing the net mg/m2/week) but some 
authors use it to describe splitting the standard scheduled dose into weekly fragments while 
maintaining the same (rather than increased) dose intensity [1].
The rationale for dose-dense treatment stems from the Norton-Simon hypothesis (Figure 1).
The rationale for dose densification extends beyond the Norton-Simon hypothesis. Firstly, 
the pharmacokinetics of a dose-dense approach may reduce toxicity. For example, paclitaxel-
induced myelosuppression is dependent on the time during which the plasma level exceeds 
50 nM [3]. This is considerably shorter for 80 mg/m2 weekly compared to 240 mg/m2 q3w [4]. 
Secondly, weekly paclitaxel may confer an additional anti-angiogenic effect compared to q3w 
scheduling [5].
Weekly paclitaxel was initially studied in the recurrent setting. Notably in one trial patients 
resistant to the q3w regimen achieved an objective response rate (ORR) of 25% with the 
weekly regimen possibly due to the additional anti-angiogenic effect of this schedule [6].
Weekly paclitaxel has also been studied in the adjuvant setting (Table 1).
Figure 1. The Norton-Simon hypothesis assumes a Gompertzian model of tumour growth (left). This was combined with 
their observation that after treatment, smaller tumours regress faster than larger ones. Crucial to their mathematical 
model is the fact that ‘log-kill’ is not constant for a given dose of therapy but instead depends on tumour size, being 
greater for smaller tumours. Their model predicts that a dose-dense approach is more likely to eradicate a tumour [2].
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In JGOG 3016 patients derived both PFS and OS benefit from the dose-dense approach, whereas 
in GOG 0262, there was no PFS difference in the intention to treat (ITT) population [7−9]. The 
two trials, however, had key differences. Patients in GOG 0262 were allowed bevacizumab 
(BEV) in an uncontrolled fashion. Since weekly paclitaxel has an anti-angiogenic effect, this 
may have been negated by the addition of BEV in 85% of the trial population. Consistent with 
this, in those who didn’t receive BEV, weekly paclitaxel improved PFS (14.2 vs. 10.3 months). 
Pharmacogenomic differences in the two trial populations may also have been important. 
There are consequently unanswered questions about dose-dense chemotherapy which may 
be answered by two phase III trials yet to report. In the 3-arm ICON 8 trial (NCT01654146), 
q3w carboplatin/paclitaxel is compared to 2 dose-dense regimens without BEV. In ICON 8B 
(NCT01654146), bevacizumab use is allowed but is controlled and pre-specified.
2.2. Understanding resistance to facilitate chemosensitization
EOC is initially chemosensitive so efforts to understand resistance could improve outcomes. 
Acquired resistance is secondary to diverse mechanisms which includes alterations to DNA 
repair and/or response to DNA damage. Mk-1775 is an anti-Wee1 tyrosine kinase inhibitor 
(TKI) that may sensitize cells to chemotherapy by abrogating the G2 checkpoint (crucial in 
P53 deficient cells) causing premature entry into mitosis [10]. It has shown promising results 
in several phase II trials [11]. In a different approach, the 2-arm PiSARRO trial (NCT02098343) 
involves the addition of APR-246 (capable of restoring mutant P53 to wild-type confirmation) 
to platinum-based therapy with the aim of restoring the apoptotic-response to chemotherapy-
induced DNA damage. There are many other pre-clinical and early clinical efforts aiming 
to reverse chemoresistance including efforts to target primary resistance by targeting cancer 
stem cells and epithelial to mesenchymal transition [12].
2.3. Novel chemotherapeutic agents
Lurbinectedin is a recently discovered marine-derived antineoplastic agent that has a multi-
modal mechanism of action similar to trabectedin. It showed promising results in a phase II 
Study Eligibility Treatment Efficacy (months) Safety (grade ≥ 3, P < 0.001)
JGOG 3016 [10] Stage II-IV Carbo q3w + either taxol 
q3w or weekly1
PFS 28.2 vs. 17.5
OS 100.5 vs. 62.2
Anaemia 69% vs. 44%
Discontinuation due to tox. 
60% vs. 43%
GOG 0262 [11] Incompletely 
resected III or IV
As above + uncontrolled 
bevacizumab2
PFS 14.7 vs. 14.0
(not significant)
Anaemia 36% vs. 16%
Neutropenia 72% vs. 83%
MITO-7 [12] Stage IC-IV Carobplatin/paclitaxel 
either q3w or weekly3
PFS 18.3 vs. 17.3
(not significant)
Neutropenia 42% vs. 50%
Thrombocytopenia 1% vs. 7%
1Carboplatin AUC 6, paclitaxel 180 mg/m2 (q3w) or 80 mg/m2 (weekly).
2Carboplatin AUC 6, paclitaxel 175 mg/m2 (q3w) or 80 mg/m2 (weekly). 84% of patients received bevacizumab.
3Carboplatin AUC 6, 175 mg/m2 (q3w) or carboplatin AUC 2, paclitaxel 60 mg/m2 (weekly).
Table 1. Comparison of phase III trials testing weekly paclitaxel in the adjuvant setting. All values given as weekly vs. q3w.
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trial in platinum-resistant EOC and is being investigated in a phase III trial against either PLD 
or topotecan [13]. It has also shown in vitro synergy with cisplatin raising hopes of clinical 
application to reverse platinum resistance [14]. Trabectedin itself is undergoing phase III test-
ing in patients with platinum partially-sensitive disease (NCT01379989).
3. Antiangiogenic strategies in ovarian cancer
Key mediators of physiological angiogenesis include products of the vascular endothelial 
growth factor (VEGF) gene family including VEGF-A (often abbreviated to VEGF), VEGF-B, C 
and D and placental growth factor. The receptor family includes VEGFR-1, 2 and 3. Different 
combinations of ligand-receptor interaction result in diverse outcomes such as promotion of 
survival, proliferation of endothelium, increased permeability and lymphangiogenesis. The 
binding of VEGF-A to VEGFR-2 is most important in endothelial proliferation and the regula-
tion of permeability [15].
In physiology VEGF is important for the cyclical angiogenesis that takes place in the female 
reproductive tract [16]. Many tumour cell lines overexpress VEGF and in one series over 97% 
of human ovarian lines had overexpression [17]. Clinically, expression levels have been found 
to be an independent prognostic factor in several studies [18] and have also been found to 
correlate with peritoneal dissemination and ascites formation [19].
Given the role of VEGF in physiology as well as pre-clinical and observational data support-
ing a role for VEGF in cancer, several VEGF-directed therapies exist.
3.1. Bevacizumab
Bevacizumab (BEV) is a humanized monoclonal antibody able to bind all VEGF-A isoforms 
[20]. It is the most extensively studied of the antiangiogenic agents in EOC. Two phase III 
studies (GOG-218 and ICON7) tested adjuvant BEV. In GOG-218 [21] patients received 
6 cycles of carboplatin/paclitaxel q3w and either 1) placebo (cycles 2–22), 2) BEV induction 
(cycles 2–6) then placebo maintenance (7–22) or 3) BEV induction (cycles 2–6) then main-
tenance (7–22). BEV was given at 15 mg/kg. The median PFS was 14.1 months in the BEV 
throughout arm compared to 11.2 months in the induction-only arm and 10.3 months for the 
control. Overall survival was not significantly different. 22.9% developed grade ≥ 2 hyperten-
sion in the BEV throughout arm vs. 7.2% in the control arm. In ICON7 [22], high-risk patients 
were given carboplatin/paclitaxel q3w with either placebo or bevacizumab (7.5 mg/kg) for 
cycles 2–18. Median PFS was 19.0 months in the BEV arm vs. 17.3 months (HR 0.81, p < 0.01). 
Among patients with incompletely resected IIIC or IV disease the median PFS was 15.9 vs. 
10.5 months in the control arm. Bleeding (39 vs. 11%), hypertension (18 vs. 2%), thromboem-
bolism (7 vs. 3%) and GI perforations (10 vs. 3 patients) were higher with BEV. Mean global 
QoL score was higher, at 54 weeks, in the control arm (76.1 vs. 69.7 points - EORTC ques-
tionnaire) [23]. Recent exploratory analysis of a ‘high-risk’ subgroup revealed significantly 
increased OS (restricted means) in the BEV group of 39.3 vs. 34.5 months [24].
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There were similarities and differences between these trials. Both suggested greater benefit in 
a subpopulation with higher stage and suboptimal debulking. They also agreed that QoL was 
not improved with BEV. Conversely, different doses and durations of treatment were used 
and overall survival data also differed, perhaps confounded by the 40% crossover in GOG 
218. BEV received regulatory approval from the EMA using 15 mg/kg [25] although ESMO 
guidelines supported the 7.5 mg/kg dose used in ICON7, which is also prescribed in the UK 
currently [26]. Analysis of both trials showed greatest separation of the PFS curves at the end 
of BEV treatment (12 or 15 months), raising questions about extending maintenance duration. 
This is being investigated in the phase III BOOST study (NCT01462890).
Bev has also been studied for recurrence. In AURELIA [27], patients with platinum-resistant 
disease and ≤2 prior lines of chemotherapy were given single agent investigator-choice che-
motherapy either alone or with BEV continued until progression/toxicity. Median PFS was 
higher in the BEV arm, 6.7 vs. 3.4 months with an ORR of 27.3 vs. 11.1%. Of the 113 patients 
with baseline ascites 17% required paracentesis in the control arm vs. 2% in the BEV arm 
and PROMs for GI symptoms were better with BEV [28]. OS was not significantly differ-
ent in the context of 40% crossover but a recent exploratory analysis suggestive a survival 
advantage in those who received BEV during or after the study [29]. Adverse events were 
consistent with previous studies. BEV has been granted FDA and EMA approval for this 
indication.
In the OCEANS study [30], the addition of BEV to carboplatin/gemcitabine in patients with 
platinum-sensitive disease resulted in a median PFS of 12.4 months vs. 8.4 months. OS was 
not significantly (38% crossover). Hypertension, proteinuria and non-CNS bleeding were sig-
nificantly more common in the BEV arm. BEV was also tested in the platinum-sensitive set-
ting with carboplatin/paclitaxel, in the factorial GOG-213 trial [31]. Median OS with BEV was 
42.2 months compared to 37.3 months without (p = 0.056). BEV has EMA regulatory approval 
in this setting.
3.2. VEGFR tyrosine kinase inhibitor (TKI) therapy
Whereas BEV binds directly to VEGF, VEGFR TKIs affect signalling via competitive inhibition 
of the intracellular kinase domain. They have the advantage of being orally bioavailable and 
multitargeted. Conversely, plasma concentration is unpredictable and off-target effects nar-
row the therapeutic window.
Cediranib inhibits VEGR-1,2 and 3 and c-Kit. ICON 6 [32] randomised patients with recurrent 
platinum-sensitive disease to chemotherapy plus: placebo concurrently + maintenance (Arm A), 
cediranib concurrently + placebo maintenance (Arm B) or cediranib concurrently + maintenance 
(Arm C). Median PFS was 11 months in Arm C vs. 8.7 months in Arm A (p < 0.0001). Recent 
OS data [33] by restricted means showed 34.2 months vs. 29.4 months in Arms C and A respec-
tively (95% CI for the difference: −0.1-9.8). During chemotherapy grade ≥ 3 fatigue (16 vs. 8%), 
diarrhoea (10 vs. 2%), hypertension (12 vs. 3%), febrile neutropenia (7 vs. 3%) and thrombosis 
(3 vs. 1%) were higher with cediranib. 48% discontinued treatment due to toxic effects in Arm 
C compared to 17% in Arm A and 37% in B. Although recent analysis showed no detriment in 
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QOL at 1 year [34], filing for regulatory approval for cediranib had been previously withdrawn. 
Nonetheless cediranib maintenance is undergoing investigation in ICON9 (see below).
Pazopanib inhibits VEGR1,2 and 3, c-Kit and PDGFR. The AGO-OVAR 16 study [35] eval-
uated first-line maintenance pazopanib. PFS was 17.9 months for pazopanib compared to 
12.3 months for control. Grade 3/4 adverse events were significantly higher for pazopanib 
including hypertension (30.8%), neutropenia (9.9%) and diarrhoea (8.2%). Discontinuation 
due to AEs occurred in 33% in the pazopanib arm compared to 5.6% in the placebo arm. 
Regulatory approval filing was withdrawn due to perceived imbalance in benefit–risk ratio.
Other VEGFR TKIs have been studied in ovarian cancer [35]. Nintedanib was given in the 
first-line setting with chemotherapy and then maintenance. Again, a PFS benefit was seen 
but no significant OS advantage [36]. Other multitargeted VEGFR TKIs such as sunitinib and 
sorafenib have also been studied with similar outcomes. As a class the TKIs appear to have 
some effect however their multi-targeted nature and unpredictable bioavailability means that 
their perceived risk:benefit ratio has not led to any regulatory approvals as yet.
3.3. Other antiangiogenic strategies
The Ang-Tie pathway is distinct from the VEGF axis, involved in vascular remodelling. 
Trebananib is peptide-Fc fusion protein that binds Angiopoietin 1 and 2 and prevents interac-
tion with Tie on endothelium. Although promising results were seen in phase II [37], a phase 
III trial (TRINOVA-2) [38] failed to meet its PFS endpoint and a third terminated early for 
futility (NCT01493505).
3.4. Combination therapy
Vascular disrupting agents (VDAs), in contrast to inhibiting formation of new vessels, target 
existing tumour vasculature. The VDA’s combretastatin and fosbretabulin disrupt the endo-
thelial cytoskeleton (by binding tubulin) aiming to cause endothelial detachment and even-
tual vessel obstruction. Tumour vasculature lacks pericytes and smooth muscle making them 
selectively susceptible. Fosbretabulin is being examined for synergy with bevacizumab and 
chemotherapy in platinum-resistant disease in a phase II/III trial (NCT02641639).
There is pre-clinical rationale for the combination of VEGF-targeted therapy with poly (ADP-
ribose) polymerase inhibitors (PARPi); anti-VEGF induced hypoxia can impair DNA repair 
and sensitize otherwise insensitive cells to PARPi. In a phase II trial of olaparib and cediranib 
[39] PFS with the combination was prolonged (17.7 vs. 9.0 months) and, consistent with pre-
clinical rationale, the difference was most marked in BRCA wild-type patients. Grade 3/4 
toxicity however was 70% with the combination vs. 7% for olaparib monotherapy. The com-
bination is currently undergoing phase III testing (ICON 9). The combination of bevacizumab 
and olaparib in first-line maintenance is also being studied (NCT02477644).
Combining VEGF blockade and immunotherapy also has pre-clinical rationale (see below). 
Combinations of anti-angiogenesis and chemotherapy have been discussed in the paragraphs 
above. Of note, an early phase trial of pazopanib with carboplatin/paclitaxel was terminated 
early because of toxicity (GI perforations and myelotoxicity).
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3.5. Predictive biomarkers in anti-angiogenic therapy
Given the relatively modest median PFS benefits and lack of OS benefit in some trials combined 
with toxicity and economic considerations, biomarkers for patient selection are needed. None 
have yet been validated for routine use although many have been suggested. Studies have 
been retrospective and focussed on different markers including gene-expression signatures, 
serum and tissue proteomic biomarkers. There have been some intriguing results including a 
63-gene signature that identifies an immune subgroup that may be harmed by bevacizumab 
treatment [40]. Prospective validation is needed for this and other candidate markers.
4. PARP inhibitor therapy
DNA constantly undergoes single and double-strand breaks (SSBs/DSBs). SSBs are repaired 
predominantly by base excision repair (BER). PARPs are nuclear proteins with diverse functions 
including in BER and chromatin remodelling. PARP-1 is the most abundant member which upon 
binding to SSBs activates its ADP-ribosyltransferase catalytic domain allowing PARylation and 
recruitment of DNA repair effectors [41]. DSBs are mostly repaired by homologous recombina-
tion (HR) or non-homologous end joining (NHEJ), the latter being error-prone [42]. HR involves 
a number of key proteins including BRCA1, BRCA2, RAD51 and PALB2. A detailed discussion 
is beyond the scope of this chapter but the process of HR is reviewed here [43]
4.1. Homologous recombination repair in ovarian cancer
The Australian Ovarian Cancer Study Group screened 1001 patients with stage I-IV ovar-
ian cancer for point mutations or large deletions in BRCA genes. 14.4% of patients overall 
had a germline mutation (including 17.1% with serous histology) [44]. A similar frequency 
was found in The Cancer Genome Atlas (TCGA) [45] although globally the prevalence varies 
between ethnic groups. In addition to germline mutations, BRCA genes can be somatically 
mutated, epigenetically silenced or the protein inactivated through post-translational mecha-
nisms, e.g. EMSY amplification [46]. Various series have found somatic mutations of BRCA in 
3–6% of EOC [47]. In contrast to somatic mutations, epigenetic silencing by promoter meth-
ylation is a dynamic process and may be harder to quantify. Studies report prevalence in the 
region of 5–30% of ovarian cancers.
However, BRCA1 and 2 are just two of many proteins involved in HR. TCGA undertook 
exomic analysis of 316 ovarian cancers as well as studies of promoter methylation, RNA 
expression and copy number changes [45]. Pathway analysis demonstrated that 51% of 
tumours had either mutations or silencing of components in the HR pathways. (Figure 2).
4.2. PARP inhibitors in ovarian cancer
HR deficiency (HRD) in EOC provides a target that can be exploited therapeutically. It was 
noted that cells with non-functioning PARP develop increased nuclear foci of Rad51 implying 
an increased burden of lesions being repaired by HR in these cells [48]. Farmer et al. [49] tested 
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the hypothesis that BRCA 1/2 dysfunction would hypersensitize cells to PARP inhibition and 
were able to demonstrate this in BRCA deficient cell lines. This example of ‘synthetic lethality’ 
whereby either defect alone is tolerable but the combination is fatal has been exploited in the 
generation of a family of drugs, the PARP inhibitors. (Figure 3).
Following this, further work began on designing a PARP inhibitor (PARPi) suitable for clini-
cal use. Early agents mimicked the substrate-enzyme interaction between NAD+ and the cata-
lytic domain of PARP1/2 and further optimization led to the design of Compound 47, that 
would be developed as Olaparib [50]. Since Olaparib, several agents have been developed 
(discussed later) designed to inhibit PARP 1/2 catalytic activity.
In addition to catalytic inhibition, a distinct antitumour mechanism of PARPi, ‘PARP-trapping’ 
has been described. Trapped PARP-DNA complexes were more cytotoxic than unrepaired 
SSBs in PARP deficient cells and different PARP inhibitors had different PARP-trapping 
potency which was not correlated with their catalytic inhibitory properties [51].
4.3. Olaparib
Olaparib is an orally bioavailable small molecule with a nicotinamide moiety that competes 
with NAD+ for binding to PARP. The MTD for olaparib was established from early phase 
Figure 2. Distribution of HR gene mutations in EOC. Adapted from Ref. [47].
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trials at 400 mg BD. Objective responses were seen mainly in patients with germline BRCA 
mutations (gBRCAm) [52] Further support for the efficacy of olaparib in in the gBRCAm pop-
ulation came from a proof-of-concept phase II where the ORR in the 400 mg BD cohort was 
33% including some complete responses (CRs) [53]. Of note, one heavily pre-treated patient 
developed acute myeloid leukaemia (AML) 9 months after cessation.
A further phase II study gave 193 heavily pre-treated EOC platinum-resistant/unsuitable 
patients with gBRCA mutations olaparib at a dose of 400 mg BD [54]. The ORR was 31%. 
AEs were similar to those seen in earlier trials with a grade 3/4 rate of 54% including anae-
mia (17%) and fatigue (6%). Two patients developed leukaemia and one myelodysplastic 
syndrome, all were heavily pre-treated (25, 26 and 34 cycles each). These results (along 
with other applicant-submitted data) earnt olaparib FDA approval as monotherapy for 
patients with gBRCA mutations after three prior lines. The recent phase III SOLO3 study 
randomised patients with gBRCA mutations who have received at least 2 prior lines of 
platinum-based therapy and who are deemed at least partially platinum-sensitive to either 
Olaparib 300 mg BD or single agent chemotherapy of investigators choice [55]. Results are 
awaited. While the previous formulation of Olaparib required 16 capsules a day, the current 
tablet formulation requires only four raising hopes that some of the gastrointestinal toxicity 
will be mitigated.
In the aforementioned studies olaparib was given as monotherapy for treatment of ‘active’ 
disease. In contrast, Study 19 randomised patients with recurrent platinum-sensitive cancer 
with at least 2 prior lines to maintenance olaparib or placebo post-chemotherapy [56]. In a pre-
defined subset analysis of patients with known germline or somatic BRCA mutation (most 
retrospectively determined), median PFS in the gBRCAm group was 11.3 vs. 4.3 months 
with Olaparib and placebo respectively (HR 0.18). OS was not significantly different (23% 
crossover). The findings led to EMA approval. SOLO2 was a phase III double-blind placebo-
controlled study in patients with recurrent platinum-sensitive EOC who had received at least 
2 prior chemotherapy lines. Patients either got maintenance olaparib 300 mg BD or placebo. 
Investigator-assessed median PFS was 19.1 vs. 5.5 months (HR 0.30). Median PFS2 was also 
Figure 3. Schematic of synthetic lethality of PARP inhibition in HR deficient cells.
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improved from not reached vs. 18.4 months (HR 0.5) and OS data are immature. Although 
nausea (76% vs. 33%) and vomitting (37% vs. 19%) were higher in the olaparib arms, grade 3/4 
events were infrequent (2.6% for both). Grade 3/4 anaemia occurred in 20%. Patient-reported 
outcomes showed no detriment for olaparib [57].
The phase III SOLO1 has completed accrual and randomised patients with BRCAm following 
first-line platinum-based chemotherapy to either Olaparib 300 mg BD or placebo.
4.4. Niraparib
Niraparib is a potent PARP1 and PARP2 inhibitor whose pharmacokinetics allows once daily 
dosing. A phase I dose escalation trial established the MTD as 300 mg/day. Dose-limiting 
toxicities included fatigue, reversible pneumonitis (in the context of recent chest wall irradia-
tion) and reversible grade 4 thrombocytopenia. Of the 20 patients with gBRCA mutations and 
evaluable tumours the ORR (at doses between 80 and 400 mg) was 40% [58].
The pivotal phase III NOVA trial enrolled patients with platinum-sensitive disease who had 
received at least two prior lines of chemotherapy and who had measurable disease of <2 cm 
post-treatment [59]. Patients were randomised to niraparib 300 mg or placebo as maintenance 
till PD or unacceptable toxicity. Patients were stratified into gBRCA mutations vs. those with-
out. Those without gBRCA mutations were further stratified into those with or without a 
positive HRD score (see below) and a predefined cut-off. PFS in the gBRCA mutated group 
was 21 vs. 5.5 months in the niraparib and control arms respectively (HR 0.30) and 12.9 vs. 
3.8 months (HR 0.45) in the HRD positive cohort.
QUADRA is an ongoing single-arm phase II trial in patients pre-treated with 3–4 lines of 
chemotherapy and who were platinum sensitive at first recurrence regardless of BRCA muta-
tion status. Patients who entered the trial underwent testing for homologous recombination 
deficiency (HRD) using a validated commercial assay. This assesses tumour samples for three 
SNP array-based ‘signatures’ of genomic instability (loss of heterozygosity, telomeric allelic 
imbalance and large scale transition) to derive an overall ‘HRD score’ that should predict 
sensitivity to PARP inhibition [NCT02354586].
PRIMA is an ongoing phase III of niraparib maintenance after 1st line chemotherapy. Unlike 
SOLO1, patients are enrolled on the basis of HRD score rather than gBRCA mutation status.
4.5. Rucaparib
Rucaparib is another orally bioavailable PARPi with both catalytic inhibitory and PARP-
trapping activity, the potency of the latter being equivalent to olaparib [60].
Rucaparib was granted accelerated FDA approval largely based on composite data from 2 
phase II studies. 106 patients with gBRCA mutations who had received at least 2 prior lines 
of chemotherapy received continuous rucaparib at 600 mg BD [61]. The confirmed ORR by 
RECIST was 54%. Toxicity at ≥ grade 3 included anaemia (27%), fatigue (15%), transient AST/
ALT elevation (13%), vomiting (6%) and nausea (4%).
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Part 1 of the ARIEL2 trial (from which the gBRCA mutation data was pooled in the above 
analysis) enrolled 206 patients who had been received at least 1 prior platinum containing 
chemotherapy regimen and who had progressed after at least 6 months after their most recent 
course [62]. Patients were prospectively divided into three subgroups based on their HRD 
status: 1) germline or somatic BRCA mutations 2) BRCA wild-type and LOH-high 3) BRCA 
wild-type and LOH-low. LOH was assessed using a next generation sequencing assay and a 
cut-off of 14% was assigned using microarray and survival data from TCGA. Based on this 
pre-specified score, PFS was 12.8 months, 5.7 months and 5.2 months in the BRCA mutated, 
BRCA wild-type/LOH-high and BRCA wild-type/LOH-low subgroups. Although median 
PFS was similar in the latter groups, the HR for PFS was significantly in favour of the LOH-
high subgroup (0.62 95% CI 0.42–0.90), and ORR by RECIST (29% vs. 10%) and 1 year sur-
vival (28% vs. 10%) were also better for the LOH-high subgroup. Of note, LOH exists on a 
continuum and exploratory post-hoc analysis revealed that a cut-off of 16% provided better 
discrimination between the two subgroups [63]. Also importantly, there were patients in the 
LOH-negative group with very good partial and even complete responses (by ca125). In this 
single arm phase II study, it is not possible to exclude the possibility that LOH-high tumours 
simply have a better prognosis and that LOH is a prognostic rather than predictive marker. In 
order to address this question (in a maintenance setting at least) the NGS assay is being pro-
spectively applied in the phase III Ariel 3 study which is investigating maintenance rucaparib 
in platinum-sensitive ovarian cancer. The phase III Ariel 4 study is will compare rucaparib as 
an active treatment vs. standard of care chemotherapy in platinum-sensitive disease after at 
least 2 prior lines.
4.6. Veliparib
Another orally bioavailable PARP inhibitor, veliparib is far less potent at PARP-trapping than 
the previously mentioned agents although it is a more potent catalytic inhibitor than nirapa-
rib and has been shown to cross the blood–brain barrier [51]. In a phase I trial 40% of the 
28 BRCAm positive evaluable patients had an ORR at the MTD (400 mg BD). Commonest 
toxicities were nausea, vomiting and lymphopenia and 2 patients had grade 2 seizures 
[NCT01472783].
In a phase II trial in patients with gBRCAm who had been treated with 3 or fewer prior 
regimens (median 2) and of whom 60% were platinum resistant, the ORR was 26% (35% in 
the platinum-sensitive cohort). Grade 3 fatigue, nausea and neutropenia occurred in 6%, 4% 
and 2% respectively with no other grade 3 toxicities. Veliparib is currently being explored in 
phase III trial concurrently with carboplatin/paclitaxel and then continued as maintenance 
(NCT02470585, see below).
4.7. Talazoparib
Talazoparib is a novel PARPi that traps PARP approximately 100-fold more efficiently than 
olaparib and rucaparib and exhibits cytotoxicity at nanomolar (compared to micromolar) con-
centrations) [60]. At an MTD of 1 mg/kg, 5/12 patients with BRCAm ovarian cancer achieved 
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an ORR with a 24% and 18% rate of G3 anaemia and thrombocytopenia respectively [64]. 
Given its unique potency for trapping, there is hope that it may have efficacy as a second line 
agent for patients who have progressed on a previous PARPi [65].
4.8. Combination therapy with PARP inhibitors
PARPi were originally developed as potential chemo/radiosensitizers. There is obvious ratio-
nale in combining PARPi with other agents, especially in tumours that are HR proficient. 
When combining PARPi with chemotherapy, rational combination necessitates consideration 
of the mechanism of action of the chemotherapy plus the relative catalytic inhibitory/trapping 
properties of the PARPi. For example, PARPi combination with topo-1 inhibitors is synergistic 
primarily because of catalytic PARP inhibition whereas synergy with alkylating agents relies 
on trapping too [66]. Several PARPi/chemotherapy combinations are in trials, reviewed here 
[67]. Synergistic toxicity (e.g. myelotoxicity) will have to be borne in mind. PARPi/VEGFR 
targeting combinations have previously been discussed. Other targeted combinations include 
PI3K/MTOR pathway inhibitors, HSP90 and CHK1/2 inhibitors [67]. Finally, talazoparib had 
immunomodulatory effects in a pre-clinical mouse model; studies looking at immunotherapy 
with PARPi are underway (NCT0257172).
4.9. Resistance to PARP inhibitors
Several putative mechanisms of resistance have been described. These include a secondary 
mutation in BRCA which either restores the correct open reading frame (i.e. where the original 
mutation caused a frameshift) or which fully reverts the original mutation to wild-type. This 
also causes platinum resistance and in one study of platinum resistance in BRCAm patients, 
46% had acquired a secondary BRCA mutation [68]. Other mechanisms include upregula-
tion of P-glycoprotein and loss of 53BP1 (which usually promotes NHEJ and prevents HR). 
Knowledge of the specific resistance mechanism may have clinical relevance as some (e.g. 
secondary mutations) cause platinum resistance too whereas others do not. Also, 53BP1 loss 
causes resistance in BRCA1 but not BRAC2 deficient tumours.
5. Immunotherapy in ovarian cancer
In 2003 Zhang and colleagues showed that the presence or absence of tumour-infiltrating 
lymphocytes (TILs) in EOC is an independent prognostic factor (in multivariate analysis) for 
PFS and OS. Of 174 patients, those with TILs had a median overall survival of 50.3 months 
compared to 18.0 months in the 72 patients without [69]. Tumour-associated antigens discov-
ered in EOC include mesothelin, Her2, NY-ESO and ca125 amongst others [70].
Around 50% of EOC has genomic/epigenetic changes in genes implicated in HRD [45]. Therefore 
there is a subset of EOC with a higher mutational burden possibly more likely to benefit from 
immunotherapy. Analysis of TCGA data showed a significantly higher predicted neoantigen 
load in HRD vs. HR proficient tumours [71]. In addition, BRCA1/2 status and neoantigen load 
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were independent predictors of OS in multivariate analysis and BRCA mutated tumours had 
an increased TIL burden and PD-L1 expression. Lastly, tumour burden/volume is an important 
factor in predicting the response to immunotherapy [72]. Ovarian cancer is unusual as patients 
presenting de novo with bulky disease can be treated with radical surgery to no residual disease. 
Although the majority relapse, there is a window of time where disease remains undetectable. 
Given the data that exists on enhanced effectiveness of immunotherapy in patients with a low 
overall tumour burden, this may present a window of opportunity to maximise effectiveness of 
this therapeutic approach.
5.1. Checkpoint blockade
Co-inhibitory checkpoints usually act to minimize collateral tissue damage during immune-
activation. Upregulation of these checkpoints can subvert anti-tumour immunity. The bind-
ing of CTLA-4 to B7.1/B7.2 is one such inhibitory interaction that can be prevented by the anti 
CTLA-4 monoclonal antibody ipilimumab.
In a phase I study including 2 patients with ovarian cancer, one patient had a 43% reduction 
in ca125 levels while the other developed a plateau in ca125 levels despite rapidly rising levels 
before treatment [73]. In a follow-up study of 9 patients one developed a radiologic PR with 
complete resolution of mesenteric lymphadenopathy. Three others achieved radiographic and 
ca125-defined stable disease of 2, 4 and >6 months duration. In a phase II study of 40 patients 
with recurrent platinum-sensitive EOC (NCT01611558), 50% developed at least G3 toxicity 
and the ORR was 10.9% by RECIST. A phase II trial testing a combination of nivolumab and 
ipilimumab for recurrent ovarian cancer is currently underway (NCT02498600).
A trial using another CTLA4 antagonist, tremelimumab, is currently enrolling patients for 
phase I trials in combination with olaparib (NCT02571725, NCT02485990).
Another inhibitory checkpoint interaction is between PD-1 (on T-cells) and PD-L1 (that may 
be upregulated on tumour cells and their microenvironment). Avelumab, a fully humanised 
IgG1 anti-PD-L1 antibody, was tested in a phase Ib trial in 124 patients with platinum resis-
tant/refractory disease after a median of 4 lines of therapy [73, 74]. The drug was well toler-
ated with a grade 3/4 adverse event rate of 6.4%. ORR in this heavily pre-treated population 
was 9.7% and the relationship between germline BRCA status and probability of response is 
being investigated. Avelumab is currently being tested in two randomised phase III trials. The 
three-arm JAVELIN Ovarian 200 study (NCT02580058)I is recruiting patients with their first 
platinum resistant/refractory relapse and randomising to either Avelumab or PLD alone or in 
combination. In JAVELIN Ovarian 100 (NCT02718417) patients with previously untreated III/
IV ovarian cancer are randomised to carboplatin and paclitaxel followed by placebo or ave-
lumab maintenance or carboplatin and paclitaxel with concurrent and maintenance avelumab.
Atezolizumab is also a fully humanized IgG1 anti-PD-L1 antibody. In the phase III ATALANTE 
trial (NCT02891824) patients with platinum-sensitive relapse are being randomised to plati-
num-based chemotherapy with concurrent and maintenance bevacizumab + placebo (control 
arm) or bevacizumab + avelumab (experimental arm). The combination of bevacizumab and 
avelumab is a rational one based on evidence that endogenous VEGF signalling has a variety 
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of immunomodulatory effects. VEGF-A has been postulated to suppress dendritic cell matu-
ration, increase the presence of immunosuppressive CD34+ haematopoetic progenitor cells 
in the tumour microenvironment and inhibit T-cell maturation [75]. Another trial combining 
atezolizumab with bevacizumab (NCT02839707) in a phase II/III setting is randomising plati-
num resistant patients between 3 arms each containing PLD with either bevacizumab alone 
(control), atezolizumab alone or bevacizumab and atezolizumab.
Instead of targeting PD-L1, pembrolizumab is a humanized anti PD-1 antibody. Keynote-028 
included 26 EOC patients. 1 patient had a CR and 2 had PR by RECIST. The median duration 
of response was not reached (range 24.9+ to 26.5+) [76]. There are currently several ongoing 
phase I/II trials with pembrolizumab both as monotherapy and in combination with chemo-
therapy, niraparib and various small molecule inhibitors in the frontline and recurrent set-
tings (NCT02865811, NCT02520154, NCT02440425, NCT02674061).
Nivolumab, a PD-1 blocking antibody, was given to 20 patients with platinum resistant EOC. 
40% of patients developed G3/4 toxicity (lymphopenia, anaemia, hypoalbuminaemia, macu-
lopapular rash, fever, ALT increase). Three patients (15%) had an OR including 2 CRs. One 
of these was in a patient with clear cell carcinoma (often chemoresistant) and this response 
was ongoing at the time of study reporting [77]. As with the pembrolizumab data, although 
the ORR was modest, there was evidence of durable responses in both studies. Nivolumab 
is being studied in several ongoing trials including in combination with ipilimumab for 
(NCT02498600), in combination with bevacizumab (NCT02873962) and with a vaccine against 
the tumour-associated antigen WT1 (NCT02737787).
5.2. Adoptive T-cell therapy
Adoptive T-cell therapy (ATT) involves the direct administration of various types of anti-tumour 
T-cells to the patient. Given the prognostic value of TILs (see above), TIL-based ATT seems logi-
cal. In one study, 13 patients who had no residual disease after surgery and adjuvant therapy 
were treated with TIL infusion. A matched control group was followed up concurrently [78]. In 
this small study 3 year OS was 100% in the TIL group vs. 67.5% in the control group. TIL-based 
trials are ongoing (NCT02482090, NCT01883297). Another ATT approach involves using chime-
ric antigen receptor (CAR) T-cells that have been engineered to express a CAR with an extra-
cellular single chain variable fragment incorporating immunoglobulin heavy and light chains 
capable of targeting any extracellular target (not just those complexed with MHC). There are 
currently over 20 trials registered on ClinicaTrials.gov testing CAR-T-cell-based therapy in ovar-
ian cancer against targets including Her2, mesothelin, folate receptor-α (FRα) and NY-ESO-1.
5.3. Other approaches
The field of immunotherapy is advancing rapidly and various other approaches are in early 
phase trials. Vaccine based therapy has yielded objective responses demonstrating proof-of-
concept, for example using a dendritic cell whole-tumour based approach [79]. Although clini-
cal trials for vaccines have been disappointing, various techniques for optimisation are leading 
to renewed enthusiasm [80]. Another approach used a tri-functional antibody, catumaxomab, 
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which binds to epithelial cell adhesion molecule (EpCAM), CD3 (found on T-cells) and has 
an Fc portion that is recognised by various cells including macrophages. This allows immune 
cells to colocalize with tumour and cause cytotoxicity. EpCAM positive cells are found in 
70–100% of malignant effusions and in a phase II study intraperitoneal (IP) administration of 
catumaxomab significantly improved the puncture free interval in heavily pre-treated patients 
[81]. It was given EMA approval for IP administration but the manufacturer withdrew this for 
commercial reasons in July 2017. One of the problems of ‘targeted’ immune therapy such as 
this is toxicity with systemic administration. Consequently, IP administration may be the only 
viable route with some therapies.
5.4. Combinations
Combination immune therapy PARP inhibitors, VEGF therapy and chemotherapy have 
already been mentioned. In addition, checkpoint inhibition has recently been combined with 
epacadostat, an inhibitor of 2,3-dioxygenase (IDO). IDO activation in tumours is associated 
with immune escape via T-cell dysfunction. Combining epacadostat and pembrolizumab has 
shown efficacy in patients with EOC although randomised trials are needed to ascertain the 
effect of epacadostat over and above pembolizumab monotherapy [82].
6. Other novel agents
The aforementioned systemic strategies are of most relevance because they are either already 
in (or close to) the clinic. There are however various other strategies being explored, some of 
which have already been trialled in clinical studies. One approach involves targeting folate 
receptor and, specifically, the α isoform (FRα). This receptor is absent from normal ovarian 
epithelium but expressed on the majority of EOC [83]. The receptor has been targeted by 
various classes of therapy including folate-drug conjugates, small molecule FRα inhibitors, 
monoclonal antibodies, vaccines and oncolytic viruses. The phase III trial of vintafolide (folate 
conjugated with a derivative of vinblastine) in combination with PLD (NCT01170650) was dis-
continued for futility. Further trials of folate-drug conjugates are ongoing [84]. Farletuzumab, 
a monoclonal antibody that causes antibody and complement- dependant cellular cytotoxic-
ity is being investigated in combination with platinum-based chemotherapy in patients with 
relapsed EOC and low ca125 following promising sub-group analysis from a previous phase 
III trial (NCT02289950). Phase I results for ONX-0801, a FRα-targeted thymidylate synthase 
inhibitor that accumulates in EOC cells generated a PR in 5/11 patients at the MTD with 4/4 
FRα expressing tumours showing response [85].
Aside from FRα targeting therapy, there are multiple other targeted strategies in EOC in 
pre-clinical and early clinical phases. Cell cycle targeting with WEE-1 inhibition has been 
discussed but other strategies including CHK1/2 inhibition with prexasertib (which yielded 
a PR in 5/13 patients in cohort 1 of a recent phase II trial [86]) are being explored. PI3k/AKT/
mTOR, Her2 and molecules in the apoptotic machinery are amongst a plethora of other ave-
nues being explored. As our understanding of the molecular basis of EOC progresses, future 
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therapies are likely to employ biomarker or other selection criteria within trial protocols. For 
example, clear cell ovarian carcinoma is known to harbour mutations in the PI3K/AKT/mTOR 
pathway and the GOG-0268 trial of temsirolimus in addition to carboplatin/paclitaxel as first-
line therapy was restricted to the clear cell population for this reason. Beyond the ‘traditional’ 
histological subtyping of EOC, analysis of TCGA data and recent advances in bioinformat-
ics as led different groups to propose various molecular classifications of high grade serous 
EOC. Once such classification proposes four subtypes; mesenchymal, immunoreactive, differ-
entiated and proliferative. Prospectively defined subgroup analysis of future trials using such 
novel molecular classifications may allow us to tailor therapy to maximise efficacy.
7. Conclusion
Several distinct strategies have been discussed. PARP inhibition have probably had the big-
gest clinical impact however mature OS data is awaited from many trials and further work is 
required to understand resistance and the potential role of combination therapy and sequenc-
ing of PARPi. Anti-angiogenic strategies have had a modest impact overall but research into 
patient selection may identify a subset who have more marked benefit. Similarly, with immu-
notherapy, the majority of patients do not show objective response but a subset has durable 
benefit. It seems, therefore that future success will depend on improved patient selection for 
trials, possibly through continued progress in understanding the molecular landscape of 
EOC. While progress has been made, there is a long way to go and the next few years should 
see continued incremental benefit in this difficult to treat disease.
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